PTC Therapeutics (PTCT) Provides Regulatory Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PTC Therapeutics Provides Key Regulatory Updates
March 19, 2024 7:30 AM EDT-Â BLA submitted to FDA for Upstaza for the treatment of AADC deficiency -
-Â NDA to be submitted mid-year for Translarna based on FDA feedback -
SOUTHÂ PLAINFIELD, N.J., March 19, 2024 /PRNewswire/ --Â PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S. FDA for Upstaza (eladocagene exuparvovec), a gene therapy for the treatment of... More
